Pathogenesis of Alzheimer’s Disease-Approached by Multiphoton Microscopy 한림의대 병리학교실 최 경찬.

Slides:



Advertisements
Similar presentations
Alzheimer’s Disease Savidra Lucatero, Vinita Mehrotra, Sabrina Rawlings, Jackie Wheeler, & Matt Zustiak.
Advertisements

Effect of Liraglutide Treatment on Inflammation and Oxidative Stress in Young and Old APP/PS1 and WT Mice Supervisors: Dr. Christian Holscher Dr. Kerry.
Etiopathogenesis of Alzheimer's disease
The Aging Brain The brain changes with age The frontal cortex & hippocampus are critical to learning, memory, planning and other cognitive activities,
Perivascular drainage of Abeta and the pathogenesis of Alzheimer’s Disease Roxana Carare University of Southampton UK.
Demyelinating Diseases. Demyelination is a common degenerative change in the nervous system secondary to neuronal or axonal injury, But in the group of.
This is only for personal educational purposes.
ALZHEIMER’S DISEASE Erin Dancey. Overview Alzheimer’s is the most common cause of dementia in adult life and is associated with the selective damage of.
Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.
ALZHEIMER'S DISEASE (AD)
MCB 135K: Discussion March 2, General Info Mid-Term I: –Avg 87 –Std. Deviation 10 –Re-grades by next Wednesday Include a cover sheet that addresses.
Anatomo-Histology From Table 8.10 Brain atrophy, flattening of gyri,
Amyloid beta protein may initiate a cascade leading to AD pathology.
Aging of the Nervous System: Functional Changes P.S. Timiras.
Alzheimer’s Disease Nicotine’s relationship and contribution to dementia.
Alzheimer’s Disease Find group of ~4 students ~ 10 minutes Discuss the following personal family connection to AD (if willing only) observations/experiences.
Case Study 63 Kenneth Clark, MD.
Alzheimer’s Disease By: Ryan Triplett. Alzheimer’s The deterioration of intellectual capabilities, memory, judgment, and personality to the extent that.
Dr. Amr Moustafa Biochemistry Unit Department of Pathology.
Dementia Research Group MRI, rates of atrophy and Alzheimer’s disease Nick Fox Dementia Research Group Institute of Neurology, UCL Queen Square, London.
Alzheimer's disease Beta amyloid protein and the potential for anti-oxidants drugs.
2 Huntington’s disease Parkinson’s disease Amylotrophic lateral sclerosis Alzheimer’s Disease Neurodegenerative Disorders.
Cerebral amyloid angiopathy (CAA) results from the accumulation of Aβ proteins primarily within the media and adventitia of small arteries and capillaries.
Protein Misfolding: Therapeutic Implications
Alzheimer’s Disease Causes, Effects, and Treatments.
How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.
Amnesia Syndromes Lesson 22. Wernicke-Korsakoff’s Syndrome n Deficits similar to H.M. l Anterograde l retrograde more severe n Cause: Long-term alcohol.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
VIII. NEURODEGENERATIVE DISEASES. - Are disorders characterized by the cellular degeneration of subsets of neurons that typically are related by function,
Introduction Alzheimer’s disease (AD) is a neurodegenerative disease associated with brain shrinkage and the loss of neurons, particularly cholinergic.
Dr. Usman Ghani CNS Block.  Pathophysiology of alzheimer’s disease: 5I.
Aging Nervous System. Neurotrophic Factors Necessary for Maintenance of Neurons Neurotrophin function o Play role in development of NS o Interact with.
New Cellular Models for Drug Discovery in Alzheimer’s Disease Jordan L. Holtzman, M.D.,Ph.D. 1,2,3 (1) Division of Environmental Health Sciences (2) Departments.
Dementia 痴呆 Jie Ming Shen, M.D., Ph.D. Department of Neurology Ruijin Hospital, SSMU.
EP Visualization of Perivascular Spaces on 3T MR Images of Alzheimer Patients: University Hospital-based Dementia Cohort Study Toshinori Hirai.
Dr. Sigal fleisher-Berkovich Neuroinflammation is regulated by angiotensin related drugs: possible implications for neurodegenerative diseases.
Phospholipids Analogs as a New Anti-Inflammatory Anti- Atherosclerosis Therapy Dror Harats The Institute of Lipids and Atherosclerosis Research, Sheba.
CLINICAL AND RESEARCH MEMORY CENTER LARIBOISIERE HOSPITAL PARIS FRANCE UNIVERSITY OF PARIS DIDEROT INSERM UNIT 942 INVOLVEMENT OF PKR IN ALZHEIMER’S DISEASE.
Epidemiology of Alzheimer’s Disease
Cerebrovascular function with aging and in Alzheimer’s disease Alzheimer’s disease, Aβ and vascular hypotheses. Assessment of cerebral autoregulation and.
Under the supervision of miklós jászberényi
Alzheimer’s Disease Today and Tomorrow First case reported in 1906 Reported by Alois Alzheimer Patient Augusta D. first treated at 46 years old Paranoia,
Alzheimer’s Disease: Advances and Hope Trey Sunderland, M.D. Chief, Geriatric Psychiatry Branch National Institute of Mental Health Bethesda, Maryland.
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
Alzheimer’s Disease- New Approach To Pathogenesis and Therapy 1 University of Wroclaw Dpt. of Psychiatry, Wroclaw, Poland 2 Dpt.of Biology and Electron.
Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part B – AD and brain systems NUCLEAR MEDICINE GRAND ROUNDS.
Diseases and Disorders of the Nervous System. schizophrenia Characterized by psychotic episodes involving hallucinations & delusions Genetic & environmental.
Trends in Biomedical Science Theories of Alzheimer’s Disease.
Pathogenesis of Alzheimer’s disease approached by multi- photon microscope Pathogenesis of Alzheimer’s disease approached by multi- photon microscope Dept.
DEGENERATIVE DISEASES is a disease in which the function or structure of the affected tissues or organs will progressively deteriorate over time, whether.
Alzheimer’s Disease and Cholesterol
Camara M1, Anscomb H.L. 2 and Baune B.T. 1,2
Aging in the CNS.
Alzheimer’s Disease Dr. Usman Ghani CNS Block.
Pilot clinical trial of curcumin for treating Alzheimer's disease
Alzheimer’s Disease CNS Block.
Alzheimer’s Disease.
Amnesia Syndromes Lecture 21.
Clayton Wiley MD/PhD.
Disorders with Complex Genetics
Athena Kalyvas, Samuel David  Neuron 
Methods Objectives Results Conclusions References
The Pathobiology of Vascular Dementia
Pathophysiology of the lymphatic drainage of the central nervous system: Implications for pathogenesis and therapy of multiple sclerosis  R.O. Weller,
The Role of Apolipoprotein E in Alzheimer's Disease
Alzheimer’s Disease Neurobiology
Volume 64, Issue 5, Pages (December 2009)
Alzheimer’s Disease Dr. Usman Ghani Neuropsychiatry Block.
Hypertension and Cerebrovascular Dysfunction
Presentation transcript:

Pathogenesis of Alzheimer’s Disease-Approached by Multiphoton Microscopy 한림의대 병리학교실 최 경찬

Contents Brief introduction Patholgic findings Pathogenic mechanism Molecular genetics Experiments and review Immunotheraphy Clinical trials

퇴행성 질환의 병리 회백질 침범 신경세포의 지속적 손실 신경세포군의 선택적 침범 증상이 서서히 발현 대부분 병인 불명

대뇌피질 침범 Alzheimer’s disease Pick’s disease Cortex & basal ganglia degeneration

Alzheimer’s disease

Alzheimer’s disease: 치매, 운동기능은 비교적 정상, 고위 대뇌 기능 장애, 65 세 이상 약 6%( 국내 ) 여자 > 남자, 유전적 요인 (55%) 아밀로이드 축적 -- 유전자 21 번 염색체 아포리포단백 -- 유전자 19 번 염색체

Estimated number of dementia patients in Korea

Pathologic Findings

현미경 소견 1) Senile plaque: amyloid 2) Neurofibrillary tangle: fibrin-- tau protein 3) Neurovacuolar degeneration 4) Hirano body 5) Neuronal loss: frontal, temporal 6) Amyloid vasculopathy: amyloid, media & adventitia, not involve brain stem Amyloid angiopathy

Cortical atrophy

Senile(neuritic) plaque Aβ-APP Microglial cells Reactive astrocytes

Neurofibrillary tangles Tau protein

Amyloid angiopathy Immunostain for anti- Aβ Ab

Pathogenic mechanism

Proposed pathogenic mechanisms for AD 1. Amyloid cascade hypothesis 2. Oxidative stress 3. Chronic inflammation 4. Perturbed lipid metabolism 5. Impaired cellular ion homeostais 6. Cerebrovascular alteration

Proposed pathogenic mechanism by Aβ

Conversion process Post-translational-modification Of protein Mutations Protein concentration pH and tissue factors Metal Ions Amyloid-associated proteins or chaperons Soluble native protein Prefibrillar intermediate Amyloid fibrils

Amyloid-associated proteins Serum amyloid-p component Apolipoprotein E(apoE) Apolipoprotein J(apoJ) Vitronectin A1-antichymotrypsin Complement proteins Glycosaminoglycans Extracellular matrix proteins

Molecular genetics

Genetics of Alzheimer Disease

β β AβPP mutations and their relationship to Aβ

Experiments and review

Amyloid Peptides Causing CAA in Humans

Sporadic CAA and AD Overlapping biology share risk factors - CAA, 46% in elderly individuals>70Ys - With AD increase frequency & severity of CAA pathology and vascular amyloid deposition >80% of all AD cases (Ellis et al, Neurology 1996)

Amyloid Deposition in Leptomeningeal Vessels: Thioflavin S Stain Nature of vessels Number counted Proportion of vessels positive for amyloid Total arteries % Total veins3524.4% Arteries <60 µ m in diameter % Arteries >60 µ m in diameter % Veins <60 µ m in diameter % Veins >60 µ m in diameter % A total of 56 blocks from seven AD brains

Why CAA rarely involves larger intra -cranial arteries Why Aβ dose not accumulate in walls of extracranial vessels Question

Origin of Aβ Mechanisim unknown - CAA in vessel wall AD in senile plaques Aβ in vessel wall - derived from vascular smooth muscle cells (Wisniewski et al, NP App Neurobiol 1996; Vinters et al, Brain Pathol 1996)

(Roy et al, Am J Pathol 1998) CAA of cortical vessels in AD 10% SDS Thioflavin S

CAA of leptomeningeal Arteries in AD Confocal microscopy Phase-contrast microscopy

Smooth muscle cells as source of Aβ Internalization of Aβ- ApoE(transport molecule)?

Periarterial pathways along which interstitial fluid drains from cerebral cortex ISF from brain drains to regional cervical LN - injection of tracers into rat brain (Cserr et al, Brain Pathol, 1992)

CAA-Related Inflammation 42 CAA patients 7/42 with inflammation & giant cell rx 35/42 without inflammation

Degree of Amyloid Angiopathy in Leptomeningeal Vessels Compared with Density of Fibrillar Amyloid Plaques in the Underlying Cortex: Thioflavin S. *No amyloid angiopathy. The mean density of plaques in the cortex underlying vessels with grade +++ amyloid angiopathy is significantly higher than plaque density with no (-), +, and ++ grades of amyloid angiopathy ( P = 0.05). Thioflavin S-stained plaques were up to 100 times less numerous than those identified by A ß immunocytochemistry. Severity of amyloid angiopathy Plaques per mm 2 cortex ±SD -*-* ± ± ± ± 0.34

Congo red 6E10

Comparison of Clinical and Genetic Characteristics of Patients with Severe CAA with or without Perivascular Inflammatory Changes CharacteristicCAA with Inflammation (n = 7)CAA without Inflammation (n = 35) Age at presentation (yr ± SD)68.3 ± 9.6 a 75.8 ± 8.3 Sex (M/F)3/410/25 Primary clinical presentation, n (%) Intracerebral hemorrhage0 (0) b 33 (94) Cognitive decline3 (43)1 (3) Seizure4 (57)1 (3) APOE genotype, n (%) b n = 7 patients genotypedn = 26 patients genotyped 4/ 45 (71) b 1 (4) 4/ (2 or 3)1 (14)12 (46) (2 or 3)/ (2 or 3)1 (14)13 (50) P<0.001

Patient No./ Age/SexClinical Symptoms at Presentation Immunosuppresive Treatment Follow-up MRI: White Matter HyperintensitiesClinical Course White Matter Hyperintensity Microhemo -rrhges WBC (/ml) Protein (mg/dl) 1/49/F1 mo cognitive declinePatchyNoneNACS × 3 daysDecreasedImproved, not to baseline Independent 2/63/M3 mo cognitive declinePatchyMultiple25 a 211 a CS × 5 daysIncreasedMinimal improvement CP × 10 daysDependent 3/69/F3 weeks gait difficulty, few months cognitive decline PatchyMultiple055CS × 6 daysNADied 2.7 years after presentation 4/71/F1 yr cognitive decline, sudden onset confusionConfluentMultiple1164 a CS × 16 daysDecreasedImproved, not to baseline Recurrent seizure Independent 5/71/F2 seizures over 1 moConfluentMultipleNACS × 1 yrDecreasedImproved, not to baseline CP × 1 yr± independent 6/73/M3 seizures over 2 months, confusion, and personality changes over few months ConfluentMultiple150 a CS × 1 moDecreasedImproved, not to baseline Recurrent seizures Died 3.2 yr after presentation 7/79/M4 months cognitive decline, seizureConfluentMultiple284*CP × 6 weeksNAImproved, not to baseline, independent MRI at presentationCSF Clinical, Laboratory, and Radiographic Characteristics of Patients with CAA-Related Perivascular Inflammation

T lymphocytes(CD3) in perivascular infiltrate including low numbers of both CD8(+) and CD4(+) lymphocytes; present B lymphocytes(CD20); absent CD3

Conclusio n This series of patients suggests that the inflammatory response to CAA can cause vascular dysfunction and cognitive impairment. The apparent response of some patients to immunosuppressive therapy points to the importance of identifying this potentially treatable form of CAA during life. Inflammation to vascular amyloid might also have a role in the meningoencephalitis reported in some AD patients treated with the experimental A  vaccine

Multi-photon confocal microscopy

Thio S Tg2576

Systemic Hypothesis (Zlokovic BV, Adv Drg Deliv Rev 2002) Vascular Hypothesis (Burgermeister et al, Ann NY Acad Sci 2000) Drainage Hypothesis (Weller et al, AmJ Pathol 1998)

Immunotheraphy

Promising treatment for AD 1.Immunotherapy 2.Amyloid formation inhibitor 3.Enzyme modulators 4.Metal-ion attenuating compounds 5. Cholesterol lowering agents

Immunotherapy & succesive animal studies First Immunotherapy using active vaccination

Preventive effect of vaccination Preventive plaque formation in hippocampus Prevention of astrocytosis

Possible treatment effect by vaccination Reduction of cortical Aβ deposition

Background

AD Transgenic Mice PDAPP mouse: Games D et al., Nature,1995 -Platelet-derived growth factor- β promoter,V717F Tg2576(APPswe)mouse:Hsiao K, Science, K670N + M671L PS-1 mouse:Duff K, Nature, 1996 Double transgenic(APPswe + PS-1) - Borchelt DR, Neuron, 1997 TgCRND8, Tg23 - V717F & K670N + M671L

Mechanism for Aβ Vaccination 1.Anti-aggregation or disaggregation by antibodies 2.Microglial mediated phagocytosis 3.Clearance of Aβ from the brain to blood

Preclinical safety and toxicology tests Animals: Mice, rats, rabbits, guinea pigs and monkeys( ) No encephalitis

Summary of vaccine studies in transgenic mouse models of AD Pathology is defined as amyloid plaque load. NC, no change

Vaccination on non-human in primate

Clinical Trial and Outcome

Clinical Trial Phase I - 20 early-moderate AD:single dose( ) - 64 early-moderate AD:multiple doses( ) - Saponin(QS-21) used as adjuvants - No encephalitis - antibodies in some patients(25%)

Phase II(Jun Jan. 2002) early-moderate AD: multiple dosese 300 with AN 1792 and 75 with placebo Clinical Trial

Withdrawl of clinical trial Development of meningoencephalitis in 18 patients Halt in Jan.2002 and withdrawl in Mar Four autopsy cases after withdrawl

Development of meningoencephalitis

Change of brain volume 3% reduction of brain volume Removal of plaques could be the reason Recovery of some lost brain volume in the second year

Possible alternatives Passive immunization Conjugation and/or modification of Aβ protein Different route of administration Appropriate adjuvants or immunomodulators

Possible problems in passive immunization Risk of cerebral hemorrhage Formation of antibodies to injected antibodies Difficulties in passage of blood brain barrier